384 related articles for article (PubMed ID: 22845482)
1. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.
Ogino S; Fuchs CS; Giovannucci E
Expert Rev Mol Diagn; 2012 Jul; 12(6):621-8. PubMed ID: 22845482
[TBL] [Abstract][Full Text] [Related]
2. Proteome Heterogeneity in Colorectal Cancer.
Lim LC; Lim YM
Proteomics; 2018 Feb; 18(3-4):. PubMed ID: 29316255
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer intratumor genetic heterogeneity: causes and implications.
Ng CK; Pemberton HN; Reis-Filho JS
Expert Rev Anticancer Ther; 2012 Aug; 12(8):1021-32. PubMed ID: 23030222
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathological epidemiology gives clues to paradoxical findings.
Nishihara R; VanderWeele TJ; Shibuya K; Mittleman MA; Wang M; Field AE; Giovannucci E; Lochhead P; Ogino S
Eur J Epidemiol; 2015 Oct; 30(10):1129-35. PubMed ID: 26445996
[TBL] [Abstract][Full Text] [Related]
5. Cancer classification in the genomic era: five contemporary problems.
Song Q; Merajver SD; Li JZ
Hum Genomics; 2015 Oct; 9():27. PubMed ID: 26481255
[TBL] [Abstract][Full Text] [Related]
6. Leveraging Single-Cell Approaches in Cancer Precision Medicine.
Nath A; Bild AH
Trends Cancer; 2021 Apr; 7(4):359-372. PubMed ID: 33563578
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunology--analysis of host and tumor factors for personalized medicine.
Ogino S; Galon J; Fuchs CS; Dranoff G
Nat Rev Clin Oncol; 2011 Aug; 8(12):711-9. PubMed ID: 21826083
[TBL] [Abstract][Full Text] [Related]
8. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.
Ogino S; Lochhead P; Chan AT; Nishihara R; Cho E; Wolpin BM; Meyerhardt JA; Meissner A; Schernhammer ES; Fuchs CS; Giovannucci E
Mod Pathol; 2013 Apr; 26(4):465-84. PubMed ID: 23307060
[TBL] [Abstract][Full Text] [Related]
10. [Role of contemporary pathological diagnostics in the personalized treatment of cancer].
Tímár J
Magy Onkol; 2013 Mar; 57(1):26-32. PubMed ID: 23573519
[TBL] [Abstract][Full Text] [Related]
11. The challenges of tumor genetic diversity.
Mroz EA; Rocco JW
Cancer; 2017 May; 123(6):917-927. PubMed ID: 27861749
[TBL] [Abstract][Full Text] [Related]
12. Integration of molecular pathology, epidemiology and social science for global precision medicine.
Nishi A; Milner DA; Giovannucci EL; Nishihara R; Tan AS; Kawachi I; Ogino S
Expert Rev Mol Diagn; 2016; 16(1):11-23. PubMed ID: 26636627
[TBL] [Abstract][Full Text] [Related]
13. Evolutionary Mechanisms of Cancer Suggest Rational Therapeutic Approaches.
Balzerano A; Paccosi E; Proietti-De-Santis L
Cytogenet Genome Res; 2021; 161(6-7):362-371. PubMed ID: 34461614
[TBL] [Abstract][Full Text] [Related]
14. Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine.
Ogino S; Nishihara R; VanderWeele TJ; Wang M; Nishi A; Lochhead P; Qian ZR; Zhang X; Wu K; Nan H; Yoshida K; Milner DA; Chan AT; Field AE; Camargo CA; Williams MA; Giovannucci EL
Epidemiology; 2016 Jul; 27(4):602-11. PubMed ID: 26928707
[TBL] [Abstract][Full Text] [Related]
15. Designing precision medicine panels for drug refractory cancers targeting cancer stemness traits.
Warrier S; Patil M; Bhansali S; Varier L; Sethi G
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188475. PubMed ID: 33188876
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic cancer subtypes--next steps into personalized medicine.
Santos C; Sanz-Pamplona R; Nadal E; Grasselli J; Pernas S; Dienstmann R; Moreno V; Tabernero J; Salazar R
Cell Oncol (Dordr); 2015 Feb; 38(1):3-16. PubMed ID: 25586691
[TBL] [Abstract][Full Text] [Related]
17. Is Personalized Medicine Here?
Carneiro BA; Costa R; Taxter T; Chandra S; Chae YK; Cristofanilli M; Giles FJ
Oncology (Williston Park); 2016 Apr; 30(4):293-303, 307. PubMed ID: 27085327
[TBL] [Abstract][Full Text] [Related]
18. Tumor heterogeneity-driven individualized therapy.
Baltagiannis EG; Ziogas DE; Cho WC; Mitsis M; Roukos DH
Future Oncol; 2021 Jan; 17(3):235-240. PubMed ID: 33305621
[No Abstract] [Full Text] [Related]
19. Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
El-Deiry WS; Taylor B; Neal JW
Am Soc Clin Oncol Educ Book; 2017; 37():e8-e15. PubMed ID: 28746017
[TBL] [Abstract][Full Text] [Related]
20. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development.
Dzobo K; Senthebane DA; Thomford NE; Rowe A; Dandara C; Parker MI
OMICS; 2018 Jan; 22(1):17-34. PubMed ID: 29356626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
